weight (LBW), preterm birth and anaemia were analysed using intention-to-treat (ITT) and per-protocol (PP) analysis. Results: Data from 910 women were analysed
because primary equivalence analyses in clinical endpoint bioequivalence (BE) studies are based on the per-protocol (PP) population (generally, completers and compliers). However, no case studies have been reported
significant difference between the two treatment arms in either the intention-to-treat or per-protocol analyses. Analysis of three protocol-specified secondary outcomes produced similar findings. The safety
lesions during a mean follow-up of 3 years. The vaccine efficacy in the per-protocol analysis was 100% against VIN 2–3 or VaIN 2–3 associated with HPV16
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.